Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT) Meeting Abstract


Authors: Ratain, M. J.; Schwartz, G. K.; Oza, A. M.; Rudin, C. M.; Kaye, S. B.; De Jonge, M. J.; Khayat, D.; Awada, A.; Sawyer, M. B.; Obel, J. C.; Medioni, J.; Evans, T. R. J.; De Greve, J.; Soetekouw, P. M.; Baurain, J.; O'Dwyer, P. J.; Hartman, C.; Poulart, V.; Walters, I. B.
Abstract Title: Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT)
Meeting Title: 47th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 29
Issue: 15 Suppl.
Meeting Dates: 2011 Jun 3-7
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2011-05-20
Language: English
ACCESSION: WOS:000208880301508
DOI: 10.1200/jco.2011.29.15_suppl.3079
PROVIDER: wos
Notes: Meeting Abstract: 3079 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Gary Schwartz
    385 Schwartz